DK1636215T3 - Furazanobenzimidazoler - Google Patents
FurazanobenzimidazolerInfo
- Publication number
- DK1636215T3 DK1636215T3 DK04733874T DK04733874T DK1636215T3 DK 1636215 T3 DK1636215 T3 DK 1636215T3 DK 04733874 T DK04733874 T DK 04733874T DK 04733874 T DK04733874 T DK 04733874T DK 1636215 T3 DK1636215 T3 DK 1636215T3
- Authority
- DK
- Denmark
- Prior art keywords
- compounds
- formula
- carbonyl group
- neoplastic
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preventing Corrosion Or Incrustation Of Metals (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03405365 | 2003-05-23 | ||
| PCT/IB2004/001723 WO2004103994A1 (en) | 2003-05-23 | 2004-05-19 | Furazanobenzimidazoles |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1636215T3 true DK1636215T3 (da) | 2008-06-02 |
Family
ID=33462273
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK04733874T DK1636215T3 (da) | 2003-05-23 | 2004-05-19 | Furazanobenzimidazoler |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US7385061B2 (es) |
| EP (1) | EP1636215B1 (es) |
| JP (2) | JP4829791B2 (es) |
| CN (1) | CN100434428C (es) |
| AT (1) | ATE384718T1 (es) |
| CA (1) | CA2526026C (es) |
| CY (1) | CY1107422T1 (es) |
| DE (1) | DE602004011515T2 (es) |
| DK (1) | DK1636215T3 (es) |
| ES (1) | ES2300775T3 (es) |
| PL (1) | PL1636215T3 (es) |
| PT (1) | PT1636215E (es) |
| SI (1) | SI1636215T1 (es) |
| WO (1) | WO2004103994A1 (es) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4656838B2 (ja) * | 2002-02-06 | 2011-03-23 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ｇｓｋ−３の阻害剤として有用なヘテロアリール化合物 |
| ES2346323T3 (es) * | 2004-02-11 | 2010-10-14 | Basilea Pharmaceutica Ag | Bencimidazoles sustituidos y su uso para inducir apoptosis. |
| US7625890B2 (en) | 2005-11-10 | 2009-12-01 | Smithkline Beecham Corp. | Substituted imidazo[4,5-c]pyridine compounds as Akt inhibitors |
| PL2459553T3 (pl) * | 2009-07-27 | 2015-03-31 | Basilea Pharmaceutica Ag | Furazanobenzimidazole jako proleki do leczenia chorób nowotworowych lub autoimmunizacyjnych |
| HUE032643T2 (en) * | 2011-01-21 | 2017-10-30 | Basilea Pharmaceutica Ag | Use of BUBR1 as a biomarker for response to furazanobenzimidazoles |
| DK2666014T3 (en) | 2011-01-21 | 2017-01-09 | Basilea Pharmaceutica Ag | USE OF GLU-tubulin as a biomarker of PHARMACEUTICAL RESPONSE TO FURAZANOBENZIMIDAZOLER |
| NZ611787A (en) | 2011-01-21 | 2015-11-27 | Basilea Pharmaceutica Ag | Use of stathmin as a biomarker of drug response to furazanobenzimidazoles |
| WO2012113802A1 (en) * | 2011-02-24 | 2012-08-30 | Basilea Pharmaceutica Ag | Use of acetylated tubulin as a biomarker of drug response to furazanobenzimidazoles |
| HUE032315T2 (en) * | 2011-03-29 | 2017-09-28 | Basilea Pharmaceutica Ag | Use of phosphorylated nude as a biomarker of drug response |
| CA2999673A1 (en) | 2015-10-22 | 2017-04-27 | Basilea Pharmaceutica International AG | Use of eb1 as a biomarker of drug response |
| WO2018197475A1 (en) | 2017-04-26 | 2018-11-01 | Basilea Pharmaceutica International AG | Processes for the preparation of furazanobenzimidazoles and crystalline forms thereof |
| US20200150109A1 (en) | 2017-05-05 | 2020-05-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Microtubule-targeting drugs as immune checkpoint inhibitors and methods of screening novel immune checkpoint inhibitors for the treatment of cancers and infectious diseases |
| EP3624790A1 (en) | 2017-05-16 | 2020-03-25 | Basilea Pharmaceutica International AG | Novel dosage principle for drugs useful for treating neoplastic diseases |
| WO2019097073A1 (en) | 2017-11-20 | 2019-05-23 | Basilea Pharmaceutica International AG | Pharmaceutical combinations for use in the treatment of neoplastic diseases |
| US20220031670A1 (en) | 2018-09-20 | 2022-02-03 | Basilea Pharmaceutica International AG | Pharmaceutical combinations for use in the treatment of neoplastic diseases |
| EP4027998A1 (en) | 2019-09-09 | 2022-07-20 | Basilea Pharmaceutica International AG | Pharmaceutical combinations comprising a furazanobenzimidazoles and a cd40 agonist for use in the treatment of neoplastic diseases |
| CN111454254B (zh) | 2020-04-26 | 2023-06-02 | 云白药征武科技(上海)有限公司 | 一种具有含氟取代基的苯并咪唑衍生物的制备及其应用 |
| CN111423429A (zh) * | 2020-05-19 | 2020-07-17 | 江西科技师范大学 | 苯并咪唑联呋咱类系列化合物及其合成方法 |
| WO2022053549A1 (en) | 2020-09-10 | 2022-03-17 | Basilea Pharmaceutica International AG | Use of c-myc as a biomarker of drug response |
| GB202101734D0 (en) * | 2021-02-08 | 2021-03-24 | Cerevance Inc | Novel Compounds |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4269846A (en) * | 1979-10-29 | 1981-05-26 | Usv Pharmaceutical Corporation | Heterocyclic compounds useful as anti-allergy agents |
| DE3100771A1 (de) * | 1981-01-13 | 1982-08-26 | USV Pharmaceutical Corp., Tuckahoe, N.Y. | Heterocyclische verbindungen, verfahren zu ihrer herstellung und sie enthaltende arzneimittel |
| DE4307105A1 (de) * | 1993-03-06 | 1994-09-08 | Cassella Ag | Hydroxymethylfurazancarbonsäurederivate |
| US6110935A (en) * | 1997-02-13 | 2000-08-29 | The Regents Of The University Of California | Benzofurazan compounds for enhancing glutamatergic synaptic responses |
| JP4656838B2 (ja) | 2002-02-06 | 2011-03-23 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ｇｓｋ−３の阻害剤として有用なヘテロアリール化合物 |
| TWI335913B (en) | 2002-11-15 | 2011-01-11 | Vertex Pharma | Diaminotriazoles useful as inhibitors of protein kinases |
-
2004
- 2004-05-19 SI SI200430636T patent/SI1636215T1/sl unknown
- 2004-05-19 CN CNB2004800177608A patent/CN100434428C/zh not_active Expired - Fee Related
- 2004-05-19 PL PL04733874T patent/PL1636215T3/pl unknown
- 2004-05-19 CA CA2526026A patent/CA2526026C/en not_active Expired - Lifetime
- 2004-05-19 DE DE602004011515T patent/DE602004011515T2/de not_active Expired - Lifetime
- 2004-05-19 AT AT04733874T patent/ATE384718T1/de active
- 2004-05-19 US US10/557,539 patent/US7385061B2/en not_active Ceased
- 2004-05-19 ES ES04733874T patent/ES2300775T3/es not_active Expired - Lifetime
- 2004-05-19 PT PT04733874T patent/PT1636215E/pt unknown
- 2004-05-19 US US12/796,135 patent/USRE42890E1/en not_active Expired - Lifetime
- 2004-05-19 JP JP2006530690A patent/JP4829791B2/ja not_active Expired - Fee Related
- 2004-05-19 DK DK04733874T patent/DK1636215T3/da active
- 2004-05-19 EP EP04733874A patent/EP1636215B1/en not_active Expired - Lifetime
- 2004-05-19 WO PCT/IB2004/001723 patent/WO2004103994A1/en active IP Right Grant
-
2008
- 2008-04-23 CY CY20081100454T patent/CY1107422T1/el unknown
-
2011
- 2011-06-21 JP JP2011137578A patent/JP5670266B2/ja not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| PL1636215T3 (pl) | 2008-09-30 |
| PT1636215E (pt) | 2008-04-29 |
| CA2526026C (en) | 2012-03-20 |
| JP2011207909A (ja) | 2011-10-20 |
| CA2526026A1 (en) | 2004-12-02 |
| SI1636215T1 (sl) | 2008-06-30 |
| JP5670266B2 (ja) | 2015-02-18 |
| DE602004011515D1 (de) | 2008-03-13 |
| CN1812986A (zh) | 2006-08-02 |
| WO2004103994A1 (en) | 2004-12-02 |
| ES2300775T3 (es) | 2008-06-16 |
| US20070043061A1 (en) | 2007-02-22 |
| US7385061B2 (en) | 2008-06-10 |
| EP1636215A1 (en) | 2006-03-22 |
| EP1636215B1 (en) | 2008-01-23 |
| DE602004011515T2 (de) | 2009-01-29 |
| JP2006528238A (ja) | 2006-12-14 |
| CY1107422T1 (el) | 2012-12-19 |
| JP4829791B2 (ja) | 2011-12-07 |
| USRE42890E1 (en) | 2011-11-01 |
| CN100434428C (zh) | 2008-11-19 |
| ATE384718T1 (de) | 2008-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1107422T1 (el) | Φουραζανοβενζιμιδαζoλες | |
| NO20050741L (no) | Ny fremgangsmate for syntesen og ny krystallinsk form av agomelatin og farmasoytiske sammensetninger inneholdende den | |
| DE602005022284D1 (de) | Substituierte benzimidazole und deren verwendung zur induktion von apoptose | |
| HUP0401889A2 (hu) | 1,8-Naftiridin-származékok mint antidiabetikumok és ezeket tartalmazó gyógyszerkészítmények | |
| SE0202133D0 (sv) | Novel compounds | |
| IS2376B (is) | Þíenópýrimidíndíón og notkun þeirra í breytingu ásjálfsnæmissjúkdómi | |
| NO20075169L (no) | Nye imidazo (1,5-A)pyndindenvater, fremgangsmate for fremstilling og farmasoytiske sammensetninger som inneholder samme. | |
| TW200724136A (en) | Pharmaceutical compositions comprising PPAR modulator | |
| SE0302116D0 (sv) | Novel compounds | |
| HK1082250A1 (en) | Thiophene carboxamides as inhibitors of the enzymeikk-2 | |
| TW200616636A (en) | Novel compounds | |
| SE0302139D0 (sv) | Novel compounds | |
| ATE482933T1 (de) | Sulfopyrrolderivate | |
| ATE381554T1 (de) | Aroylfurane und aroylthiophene, die sich für die behandlung von krebs eignen | |
| DE602004008959D1 (de) | Benzoäbüä1,4üdioxepinderivate | |
| SE0300092D0 (sv) | Novel compounds | |
| SE0402925D0 (sv) | Novel Compounds | |
| SE0300456D0 (sv) | Novel compounds | |
| MXPA05010020A (es) | Derivados de oxamida. | |
| ATE485822T1 (de) | Phenylaminopyridine und phenylaminopyrazine | |
| SE0401763D0 (sv) | Compounds | |
| SE0303280D0 (sv) | Novel compounds | |
| SE0303090D0 (sv) | Novel compounds | |
| MXPA05014068A (es) | Dicetopiperazinas sustituidas y su uso como antagonistas de oxitocina. | |
| SE0302755D0 (sv) | Novel compounds |